Advicenne S.A. (EPA:ALDVI)

Market Cap	24.65M
Revenue (ttm)	5.90M
Net Income (ttm)	-6.21M
Shares Out	14.17M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,742
Average Volume	27,607
Open	1.752
Previous Close	1.750
Day's Range	1.674 - 1.752
52-Week Range	1.104 - 2.200
Beta	0.91
RSI	54.02
Earnings Date	Dec 19, 2025

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2024, Advicenne's revenue was 5.27 million, a decrease of -0.51% compared to the previous year's 5.30 million. Losses were -6.46 million, -14.13% less than in 2023.